Steris (BSP:S1TE34) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:S1TE34 Steris PLC BSP:S1TE34
23 GF Score
Price R$52.14
GF Value R$60.72
! 1 Warning Sign
View Full Analysis

What is Steris FFO?

FFO (Funds from operations) only applies to REITs.

BSP:S1TE34
23GF Score
Steris PLC BSP:S1TE34
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Steris (BSP:S1TE34) Overvalued in 2026?

Based on GuruFocus' analysis, Steris stock appears to be undervalued. The current stock price of R$52.14 is trading 14.1% below its estimated GF Value™ of R$60.72.

Key valuation signals for BSP:S1TE34:

  • FFO:
  • GF Value™: R$60.72 vs. price of R$52.14 (14.1% below fair value)
  • GF Score™: 23/100 with 1 warning sign

No single metric tells the full story. See the BSP:S1TE34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Steris Business Description

Other Exchanges STE:USA2TG:Germany
Address 70 Sir John Rogerson\'s Quay, Dublin, IRL, D02 R296
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
23GF Score

Get the complete analysis for BSP:S1TE34

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$52.14
Price
R$60.72
GF Value